Could Viking Therapeutics Be the Next Eli Lilly?

Viking Therapeutics is advancing VK2735, a dual GLP-1/GIP weight-loss candidate, with injectable VK2735 in phase 3 and the oral version expected to enter phase 3 in Q4. The article notes phase 2 results showing weight-loss reductions of more than 14% after 13 weeks, but argues Viking is unlikely to displace Lilly given Lilly's 60% share of the U.S. GLP-1 weight-loss market and stronger commercial/manufacturing scale. The piece is more a market comparison and stock-pitch commentary than a near-term catalyst.

Analysis

VKTX is a classic “credible option value” biotech rather than a clean fundamental rerating story. The real market signal is not that it can beat Lilly head-on, but that it can become a monetizable third lane in a category where prescribers are already educated and payer pathways are forming; that lowers commercial adoption friction if late-stage data stay clean. The oral + injectable angle matters because it expands TAM by targeting two distinct use cases: chronic maintenance convenience for oral and rapid titration/efficacy for injectable, which could support multi-billion-dollar peak sales even without category leadership.

The main second-order effect is competitive pressure on Novo and Lilly’s pricing power, not their unit volumes. If VKTX advances, expect the incumbents to respond with contracting, patient-support, and manufacturing incentives rather than headline price cuts; that usually compresses future margin assumptions more than current-period revenue. The bigger indirect winner could be the API/CDMO and fill-finish ecosystem if Viking scales, because small biopharma winners tend to outsource heavily until they reach very high volume thresholds.

Near term, the stock is still a binary event-driven setup around phase 3 initiation/readout sequencing, with the biggest upside coming from de-risking, not from commercial sales. The tail risk is that the market is already extrapolating Lilly-like efficacy from phase 2, so any tolerability issue, slower titration, or discontinuation signal would likely hit harder than an efficacy miss. Over a 6-12 month horizon, the key variable is whether Viking can demonstrate not just weight loss, but a differentiated convenience/safety profile that justifies adoption versus “good enough” incumbent products.

Consensus may be underestimating how much of the obesity trade is now about manufacturing reliability and payer access rather than molecule quality. That makes VKTX less of a winner-take-all disruptor and more of a call option on execution; upside is large if it clears late-stage hurdles, but the path to sustained share is much narrower than the headline market size suggests.

Key Decisions for Investors

• Long VKTX only as a catalyst trade into phase 3 milestones; size small and use a 3-6 month horizon. Upside is convex if data validate phase 2, but the position should be treated as high-volatility event risk, not a core book holding.
• If already long NVO, hedge with a modest VKTX starter long rather than outright selling NVO. This captures category expansion while reducing exposure to margin compression if a credible third entrant gains traction over the next 6-12 months.
• Avoid chasing VKTX after strength; prefer buying pullbacks following neutral/positive trial commentary. The stock likely discounts future optimism quickly, while downside from tolerability or enrollment issues can reprice the name 20-30% in a single session.
• Use option structures instead of common stock for VKTX: call spreads dated past the next clinical catalyst offer better risk/reward than equity because implied volatility should stay elevated and binary downside is material.
• Monitor NVO and other GLP-1 suppliers for second-order beneficiaries in manufacturing and delivery services; any signal that Viking is outsourcing broadly could be a relative-long in CDMO/fill-finish names versus the direct equity exposure.